CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 52 enrolled
Drug / intervention
Medtronic CoreValve™ Evolut™ PRO Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982588
NCT04982588N/AActive
CompareCT.gov

Medtronic CoreValve™ Evolut™ PRO System China Clinical Study

Medtronic Cardiovascular·interventional·Posted Jul 29, 2021·Updated Dec 3, 2025

In Brief

A clinical study evaluating Medtronic CoreValve™ Evolut™ PRO System for Severe, Symptomatic Aortic Stenosis. Active but no longer recruiting, targeting 52 participants across 4 sites.

Detailed Summary

Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™ PRO System when used by China implanting centers in Chinese patients with severe symptomatic aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere, Symptomatic Aortic Stenosis
CountriesChina
Collaborators--

Timeline

N/AActive
2022202320242025202620272028
First PostedJul 29, 2021
Enrollment StartJul 17, 2021
Primary CompletionMar 17, 2023
Study CompletionMay 15, 2028
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.9 years ago

Interventions

Medtronic CoreValve™ Evolut™ PRO Systemdevice

The system comprised of the following three components: 1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV) 2. EnVeo™ PRO Delivery Catheter System (DCS) 3. EnVeo™ PRO Loading System (LS)